EPS for bluebird bio, Inc. (BLUE) Expected At $-2.81

October 14, 2018 - By Dolores Ford

bluebird bio, Inc. (NASDAQ:BLUE) LogoInvestors sentiment increased to 1.4 in Q2 2018. Its up 0.41, from 0.99 in 2018Q1. It increased, as 36 investors sold bluebird bio, Inc. shares while 69 reduced holdings. 49 funds opened positions while 98 raised stakes. 51.83 million shares or 0.73% more from 51.45 million shares in 2018Q1 were reported.
Contravisory Invest Management holds 500 shares or 0.03% of its portfolio. State Of Alaska Department Of Revenue, Alaska-based fund reported 5,790 shares. Shell Asset Management stated it has 0.02% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Daiwa Secs Group Inc Inc reported 15,515 shares. Prelude Cap Mgmt Llc, New York-based fund reported 111 shares. Gotham Asset Ltd Liability Company has invested 0.01% in bluebird bio, Inc. (NASDAQ:BLUE). Jefferies Group Ltd Liability holds 0.01% or 14,200 shares. Legal And General Gp Public Ltd Co holds 22,782 shares or 0% of its portfolio. Fortaleza Asset Mngmt owns 455 shares. Alliancebernstein Lp invested in 321,540 shares or 0.04% of the stock. Grp One Trading Limited Partnership stated it has 54,929 shares or 0.07% of all its holdings. Bancshares Of America Corporation De has invested 0% in bluebird bio, Inc. (NASDAQ:BLUE). Bnp Paribas Asset Mngmt Hldg Sa holds 0.08% or 57,792 shares in its portfolio. 94,846 are owned by Frontier Limited Com. Neuberger Berman Gp Limited Liability Company holds 0% or 6,208 shares in its portfolio.

Analysts expect bluebird bio, Inc. (NASDAQ:BLUE) to report $-2.81 EPS on November, 7.They anticipate $1.08 EPS change or 62.43 % from last quarter’s $-1.73 EPS. After having $-2.91 EPS previously, bluebird bio, Inc.’s analysts see -3.44 % EPS growth. The stock decreased 0.43% or $0.55 during the last trading session, reaching $126.09. About 717,422 shares traded or 7.98% up from the average. bluebird bio, Inc. (NASDAQ:BLUE) has risen 15.36% since October 14, 2017 and is uptrending. It has underperformed by 0.26% the S&P500.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Coverage

Among 8 analysts covering Bluebird Bio (NASDAQ:BLUE), 5 have Buy rating, 1 Sell and 2 Hold. Therefore 63% are positive. Bluebird Bio had 12 analyst reports since May 2, 2018 according to SRatingsIntel. The firm has “Hold” rating by Oppenheimer given on Monday, June 4. PiperJaffray reinitiated the shares of BLUE in report on Thursday, May 31 with “Overweight” rating. Oppenheimer maintained the shares of BLUE in report on Wednesday, May 2 with “Hold” rating. The stock has “Hold” rating by Oppenheimer on Friday, June 15. Bernstein maintained bluebird bio, Inc. (NASDAQ:BLUE) rating on Monday, May 7. Bernstein has “Hold” rating and $19400 target. BMO Capital Markets maintained it with “Outperform” rating and $216 target in Thursday, May 3 report. The company was maintained on Friday, June 15 by BTIG Research. The company was upgraded on Tuesday, June 19 by Evercore. The rating was maintained by BTIG Research on Wednesday, May 2 with “Buy”. The stock of bluebird bio, Inc. (NASDAQ:BLUE) has “Sell” rating given on Sunday, June 3 by Cantor Fitzgerald.

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer in Cambridge, Massachusetts and Seattle, Washington. The company has market cap of $6.83 billion. The Company’s product candidates include Lenti-D that is in phase II/III clinical studies for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in four clinical studies for the treatment of transfusion-dependent ??-thalassemia, and severe sickle cell disease. It currently has negative earnings. The company's lead product candidate in oncology is bb2121, a chimeric antigen receptor T cell product candidate that is in a Phase I trial for the treatment of relapsed/refractory multiple myeloma. bluebird bio, Inc. has a strategic collaborations with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Kite Pharma, Inc. to develop and commercialize second generation T cell receptor product candidates against an antigen related to certain cancers associated with the human papilloma virus.

More notable recent bluebird bio, Inc. (NASDAQ:BLUE) news were published by: Streetinsider.com which released: “bluebird bio (BLUE) Granted EMA Approval for Marketing Authorization of LentiGlobin Gene Therapy” on October 05, 2018, also Fool.com with their article: “Here’s Why bluebird bio Dropped 13.3% in September” published on October 11, 2018, Seekingalpha.com published: “Premarket analyst action – healthcare” on September 21, 2018. More interesting news about bluebird bio, Inc. (NASDAQ:BLUE) were released by: Seekingalpha.com and their article: “Orchard Rx files for IPO of American shares” published on October 04, 2018 as well as Fool.com‘s news article titled: “Why bluebird and Celgene Should Worry About Amgen’s Latest Clinical Victory” with publication date: September 14, 2018.

bluebird bio, Inc. (NASDAQ:BLUE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News